Last reviewed · How we verify

HAIC of FOLFOX — Competitive Intelligence Brief

HAIC of FOLFOX (HAIC of FOLFOX) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (regional delivery). Area: Oncology.

marketed Chemotherapy combination (regional delivery) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HAIC of FOLFOX (HAIC of FOLFOX) — Tianjin Medical University Cancer Institute and Hospital. HAIC (hepatic arterial infusion chemotherapy) of FOLFOX delivers chemotherapy directly into the hepatic artery to treat liver cancers with high local drug concentration.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HAIC of FOLFOX TARGET HAIC of FOLFOX Tianjin Medical University Cancer Institute and Hospital marketed Chemotherapy combination (regional delivery)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (regional delivery) class)

  1. Tianjin Medical University Cancer Institute and Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HAIC of FOLFOX — Competitive Intelligence Brief. https://druglandscape.com/ci/haic-of-folfox. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: